Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943184 | 1.00 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL2123828 | 0.86 | CACNA1B (0.43) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL31735392 | 0.86 | TDP1 (0.56) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL2123823 | 0.85 | ALDH1A1 (0.48) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL11656014 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL17199131 | 0.83 | CACNA1B (0.47) | ALDH1A1TDP1LMNAGRIK1GRIK2 | |
| SCHEMBL2421447 | 0.82 | GRIK1 (0.65) | ALDH1A1TDP1GRIK1GRIK2HPGD | |
| SCHEMBL2125023 | 0.82 | GRIK1 (0.45) | ALDH1A1GRIK1GRIK2HPGDMTNR1A | |
| SCHEMBL2123801 | 0.80 | ALDH1A1 (0.46) | ALDH1A1GRIK1GRIK2MTNR1AMTNR1B | |
| SCHEMBL2122716 | 0.80 | ALDH1A1 (0.58) | ALDH1A1LMNAGRIK1GRIK2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12263159-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2024-08-29 | — | — | US | disclosed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| US-11918568-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3818053-B1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2021-11-25 | — | — | US | disclosed |
| EP-3818053-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112654608-A | Condensed ring compounds having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2021-04-13 | — | — | CN | disclosed |
| US-8871948-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-10-28 | — | — | US | disclosed |
| EP-2444392-B1 | Intermediary (aza)indole derivative substituted in position 5 | ACRAF (IT) | 2014-09-24 | — | — | EP | disclosed |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | AZIENDE CHIMICHE RIUNITE ANGELIN FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2013-06-20 | — | — | US | disclosed |
| EP-2234968-B1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | ACRAF (IT) | 2013-03-27 | — | — | EP | disclosed |
| US-8399477-B2 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESO A.C.R.A.F. S.P.A. (IT) | 2013-03-19 | — | — | US | disclosed |
| CN-101910127-B | (AZA) INDOLE DERIVATIVE SUBSTITUTED IN THE 5 POSITION, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, INTERMEDIATE COMPOUND AND PROCESS FOR PREPARING THE SAME | ACRAF | 2013-01-23 | — | — | CN | disclosed |
| EP-2444392-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2012-04-25 | — | — | EP | disclosed |
| CN-101910127-A | (AZA) INDOLE DERIVATIVE SUBSTITUTED IN THE 5 POSITION, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, INTERMEDIATE COMPOUND AND PROCESS FOR PREPARING THE SAME | ACRAF | 2010-12-08 | — | — | CN | disclosed |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | Aziende Chim. Riun.Ang.Franc. A.C.R.A.F.S.P.A. (IT) | 2010-11-11 | — | — | US | disclosed |
| EP-2078711-A1 | (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 2009-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | NAMPT, NME4, NDUFAB1 | ALDH1A1 1608/4885TDP1 3565/4885LMNA 1861/4885 |
| US-20210361636-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, ABAT | ALDH1A1 1751/4885TDP1 3766/4885LMNA 1939/4885 |
| US-11918568-B2 | Fused ring compound having urea structure | NAMPT, NME4, ABAT | ALDH1A1 1751/4885TDP1 3766/4885LMNA 1939/4885 |
| US-20100286189-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | ALDH1A1 582/4885TDP1 2228/4885LMNA 2017/4885 |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, NDUFAB1 | ALDH1A1 1608/4885TDP1 3565/4885LMNA 1861/4885 |
| US-20130158269-A1 | (AZA)INDOLE DERIVATIVE SUBSTITUTED IN POSITION 5, PHARMACEUTICAL COMPOSITION COMPRISING IT, INTERMEDIATE COMPOUNDS AND PREPARATION PROCESS THEREFOR | IDO1, CYP51A1, WEE1 | ALDH1A1 582/4885TDP1 2228/4885LMNA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.